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ACCORD Glycemia Results Continue to
Puzzle
“I
f I had a world of my own, everything
would be nonsense. Nothing would
be what it is, because everything
would be what it isn’t. And contrary wise,
what is, it wouldn’t be. And what it
wouldn’t be, it would.”
This quote by Alice from the Disney
ﬁlm version of Alice in Wonderland by
Lewis Carroll may make sense in the
world she experiences. In our world, Al-
ice’swishisusuallynotfulﬁlled,butsome
ﬁndings of the Action to Control Cardio-
vascular Disease in Diabetes (ACCORD)
glycemic control study may be an
exception.
The report by Riddle et al. (1) in this
issue of Diabetes Care attempts to explain
in an observational post hoc analysis of
the ACCORD trial whether features of
glucose control explain the higher ob-
served death rate in the intensive com-
pared with the standard glycemic control
treatment arms (2). All the provisos asso-
ciated with observational research must
be kept in mind when interpreting this
analysis, which does not have the same
high standard of evidence as testing pre-
speciﬁed hypotheses of a randomized
controlled trial. The ACCORD trial as-
sessed the effects of several interventions
directed at blood pressure, dysipidemia,
andhyperglycemiaondiabetesoutcomes.
The results of the glucose control aspect
of the trial deﬁed expectations when it
was announced that the intensive glucose
control arm was prematurely terminated
due to higher mortality associated with
assignment to this treatment. Because the
target A1C in this arm was normoglyce-
mia,i.e.,anA1C6.0%,thenumberone
suspect has been that hypoglycemia ex-
plains the greater event rate noted with
intensive therapy. The result reported by
Riddle et al. in this article, though, is not
what was expected and would please Al-
ice. Overall, they found no evidence to
suggest that lower average A1C was asso-
ciated with higher mortality, as would
have been expected if hypoglycemia had
been the cause of death. In fact, a higher
mortality rate was observed in both the
intensive and standard therapy arms for
individuals with a higher average and last
recordedA1C.Thisresultwasstatistically
signiﬁcant in the intensive treatment arm
only, and the authors also observed a sig-
niﬁcant interaction such that the mag-
nitude of this effect in the intensive
treatment arm exceeded that seen in the
standard arm beyond what would be ex-
pected by chance. The ﬁtted plot of mor-
tality hazard ratio by study average A1C
in Fig. 1 supports the presence of a linear
associationbetweenthesemeasuresinthe
intensive treatment arm (1).
The ACCORD trial attempted to
quickly achieve the target A1C in the inten-
sive treatment arm, as demonstrated by the
precipitous decline in this measure occur-
ringduringtheﬁrstyearofthetrial(supple-
mental Fig. A1, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1278/DC1) (1).
Hence a too rapid drop in A1C became
another suspect for the higher mortality
rate and led to an examination of change
during the ﬁrst year and even the ﬁrst 4
months of the trial as predictors of mor-
tality. In all these comparisons, a decline
inA1Cwasassociatedwithalowerriskof
mortality, which was statistically signiﬁ-
cant for the 1-year difference only, as op-
posed to the higher risk that would have
been expected if an early rapid reduction
in A1C had been responsible for excess
mortality. An examination of event rate
versus study time (supplemental Fig. A2)
alsoarguesagainstanearlyexcessmortal-
ity with intensive treatment (1). The ex-
cess mortality in the intensive arm does
notappearuntilafteryear2.Figure2pro-
vides general support for the ﬁnding of
lower mortality associated with a decline
in A1C, but also portrays in the intensive
arm only a higher risk of mortality among
individuals whose A1C did not change or
increasedsomewhat(1).Thisﬁndingsug-
gests that lack of response to an intensive
glucose control strategy may lead to a
higher event rate in this population, or,
alternatively, that the lack of response
identiﬁes individuals at higher risk for
mortality for reasons unrelated to the
treatment strategy.
TheanalysisofRiddleetal.conﬁrmed
the results that we all would have ex-
pected regarding lower mortality associ-
ated with better glycemic control, except
for the main outcome of interest, which
went in the opposite direction. Of course,
there are other questions that quickly
come to mind regarding hypoglycemia in
this trial. Was hypoglycemia directly im-
plicated in the deaths of subjects? Does
the lower A1C expected in the intensive
treatment arm predict a higher risk of hy-
poglycemia? The ACCORD investigators
have already examined these issues in
publications that will have appeared by
the time this editorial is published. The
results of these analyses continue to run
counter to what we would have expected
and fail to support hypoglycemia as the
cause of the excess number of deaths in
the intensive treatment arm. Of the
10,194 subjects in the ACCORD study
whohadatleastoneassessmentforhypo-
glycemia,451deathsoccurredtothetime
that the study was terminated, but only 1
was adjudicated as being directly related
to hypoglycemia (3). More hypoglycemic
eventsoccurredintheintensivetreatment
arm, and a higher risk of mortality was
seen in individuals who experienced one
ormoreofsuchevents.Yettheproportion
of deaths that could be attributed to hy-
poglycemia was low and of similar mag-
nitude in the intensive (5.9%) compared
with the standard (5.1%) treatment arms.
Regarding the prediction of hypoglyce-
mic events, the ACCORD data demon-
strated that these events increased in
frequency with poorer glucose control as
reﬂected by greater average A1C over the
course of the study in both treatment
groups, not lower values as one might
have expected (4).
So, to reiterate, a clinical trial of in-
tensive glucose control resulted in
higher mortality due to the interven-
tion. Reasonable assumptions to ex-
plain this ﬁnding include 1) better
glucose control results in hypoglyce-
mia, 2) hypoglycemia results in an ex-
cess of deaths, and 3) better glucose
control is related to higher mortality.
None of these is what it is. A clue, if
there is one to be found, may be the
higher mortality associated with resis-
tance to glucose control seen in Fig. 2.
Whethercontinuingtopursueintensive
treatment in patients in whom no im-
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more harm than good should be pur-
sued as a possible explanation for the
puzzling ﬁndings of ACCORD and an
exit for us all out of Wonderland.
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